Today's Edition
ABU DHABI (WAM)
M42, a global health leader powered by technology, continues to pioneer artificial intelligence (AI) and genomics-driven medical and clinical solutions as part of its mission to revolutionise health in the UAE and globally.
The largest healthcare company in the Middle East will showcase the unparalleled spectrum of diagnostic capabilities at the ADLM Middle East Conference and Exposition, held from 23rd to 24th November 2024 at Conrad Abu Dhabi Etihad Towers.
Spanning the full spectrum of diagnostics, M42’s offering is anchored by the advanced capabilities of the National Reference Laboratory (NRL) and the Omics Centre of Excellence and supported by a world-class team of clinical experts.
Organised by the Association of Diagnostics & Laboratory Medicine (ADLM), a global scientific and medical professional organisation dedicated to clinical laboratory science and its application to healthcare, the event will bring together leading laboratory medicine professionals to explore current trends in diagnostic innovation.
M42’s National Reference Laboratory plays a vital role in the UAE’s healthcare landscape, performing over 10 million diagnostic tests annually.
It leverages scientific expertise, AI, and advanced connectivity to develop proprietary solutions that detect complex disorders in an efficient, high-quality environment.
It covers the full diagnostic spectrum with over 5,000 tests available across its 10 state-of-the-art laboratories.
This robust testing capability elevates the quality and efficiency of laboratory services in the region, supporting comprehensive clinical needs and reducing turnaround times.
Chief Executive Officer of NRL, Dr. Laila AbdelWareth, said, “The National Reference Laboratory is committed to driving continuous medical education around laboratory medicine and bringing international best practices to the region. Our internationally accredited laboratories, operated by a world-class team of pathologists and clinical and biomedical scientists, bring specialised expertise across various disciplines of medicine. By staying at the forefront of technological advancements and adapting to the changing needs of the community, we continue to play a crucial role in improving patient outcomes, supporting public health initiatives driven in partnership with policymakers, and enhancing the overall healthcare infrastructure in the UAE.”
M42’s Omics Centre of Excellence is the operator of the Emirati Genome Programme (EGP) led by the Department of Health — Abu Dhabi.
Having sequenced the genomes of over 600,000 Emiratis, this national effort is transforming healthcare in the UAE, enabling the shift from a traditional one-size-fits-all approach to a precise, prevention-based one and setting a global benchmark for population genomics.
The EGP has introduced large-scale initiatives, such as premarital screening and pharmacogenomics, enabled by comprehensive genetic data, allowing for early identification of genetic risks to empower patients with actionable insights, often shortening prolonged diagnostic journeys and alleviating financial burdens.
Medical Director of Clinical Genomics at M42’s Omics Centre of Excellence, Dr. Val Zvereff, said, “Through operating the Emirati Genome Programme (EGP), M42 is revolutionising healthcare in the UAE with population-scale genomic initiatives that enable preventive, precise and predictive care. Programmes like premarital screening leverage comprehensive genetic data to identify hereditary risks early, while whole genome sequencing offers unparalleled diagnostic accuracy, increasing diagnostic yield for rare diseases by 31 percent compared to standard tests. This transformative approach is reshaping healthcare delivery, moving beyond data collection to practical applications that empower clinicians with actionable insights. By advancing accurate diagnoses, tailored treatments and preventive care strategies, the EGP is redefining the standard of care and paving the way for a healthier future.”
